98%
921
2 minutes
20
Clinical Relevance: Understanding devices used for vision screening, including their potential utilisation and validity, will facilitate proper utilisation of this technology.
Background: The Acuidrive is a self-illuminated, hand-held, visual acuity screening device intended for use in policing, with visual acuity assessed roadside to identify drivers who may not meet vision standards for driving. The target is presented binocularly at 24 cm, and +4.00 D lenses eliminate the accommodation requirement. This study investigates its validity and applicability relative to the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart.
Methods: There were 36 participants, half younger adults aged 18-30 years and half older adults aged 50-70 years. The subjects underwent binocular visual acuity testing using the Acuidrive device and an ETDRS chart displayed on a monitor. Eyes were corrected for distance using lenses in a trial frame, and additional trial lenses provided four blur levels: zero, +0.50 DS, +1.00 DS and +1.50 DS. Luminances for the devices were similar at approximately 100 cd/m. ETDRS chart measurements were conducted both with room lighting on and off.
Results: The Acuidrive device underestimated the ETDRS visual acuity across all blur levels, with mean differences of 0.24 ± 0.07 logMAR and 0.18 ± 0.10 logMAR for room lights on and off, respectively. To predict ETDRS visual acuity of poorer than 0.34 logMAR (6/12), a screening level of 0.50 logMAR (6/19) with the Acuidrive device provided high sensitivity and specificity (86% and 79% with lights-on, and 85% and 78% with lights-off). Visual acuity was better for the older group than the younger group by approximately 0.10 logMAR.
Conclusion: There was an offset of 0.2 logMAR (two lines) between visual acuity measures for the Acuidrive device and an ETDRS chart. The Acuidrive device has the potential to be a viable screening tool with refinement to its construction.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/08164622.2023.2255867 | DOI Listing |
J Cataract Refract Surg
July 2025
Helsinki Retina Research Group, University of Helsinki, Finland.
Topic: To compare the outcomes of surgical approaches to correct ametropia following cataract and lens surgery.
Clinical Relevance: Despite advancements in the field of biometry and intraocular lens (IOL) power calculation formulas, complete elimination of refractive surprises following cataract and lens surgery is impossible. Preferred Practice Patterns acknowledges the possibility of refractive surprise following cataract surgery; however, no recommendations regarding the preferred treatment have been given.
Cornea
September 2025
Department of Ophthalmology, University of Duesseldorf, Duesseldorf, Germany.
Purpose: To report a case of late dehiscence of an EndoArt implant and its successful management 10 months after initial implantation.
Methods: Case report.
Results: A 73-year-old man with a history of multiple failed Descemet membrane endothelial keratoplasty procedures on the right eye underwent EndoArt implantation for bullous keratopathy.
Graefes Arch Clin Exp Ophthalmol
September 2025
Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College Hospital, No. 1 Shuaifuyuan Wangfujing Dongcheng District, China, 100730, Beijing.
Purpose: To evaluate the predictive value of the preoperative orientation and offset of angle alpha(chord alpha) and angle kappa(chord mu) for visual outcomes in patients who underwent trifocal intraocular lens (IOL) implantation.
Methods: Patient records of eyes that underwent AT LISA tri 839MP implantation were retrospectively collected and grouped according to the preoperative offset and orientations of chord alpha and chord mu. The two-dimensional location of each angle was described by the interaction of the orientation and offset.
Retin Cases Brief Rep
October 2024
Eye Clinic, Humanitas-Gradenigo Hospital, Torino, Italy.
Purpose: To study the efficacy and safety of pro re nata regimen of brolucizumab, without loading dose, in treatment-naive patients with neovascular age-related macular degeneration (nAMD).
Case Series: Retrospective, observational study. We included all consecutive patients diagnosed with treatment- naïve nAMD undergoing Brolucizumab in Humanitas eye clinic, Turin, Italy between April 2022 and May 2023.
J Ophthalmic Vis Res
September 2025
Clinical Research Development Unit, Shafa Hospital, Kerman University of Medical Sciences, Kerman, Iran.
Purpose: To evaluate the time required for refractive error (RE) stabilization after standard phacoemulsification cataract surgery and identify preoperative factors influencing this duration.
Methods: This prospective case series study enrolled patients who had undergone phacoemulsification cataract surgery. RE stabilization was defined as 0.